City of Hope Medical Center

A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6 (2024) Hughes BG, Guminski A, Bowyer S, Migden MR, Schmults CD, Khushalani NI, Chang ALS, et al. Journal article Novel MAGIC composite scores using both clinical symptoms and biomarkers best predict treatment outcomes of acute GVHD (2024) Akahoshi Y, Spyrou N, Weber D, Aguayo-Hiraldo P, Ayuk F, Chanswangphuwana C, Choe HK, et al. Journal article Flares of acute graft-versus-host disease: a Mount Sinai Acute GVHD International Consortium analysis. (2024) Akahoshi Y, Spyrou N, Hoepting M, Aguayo-Hiraldo P, Ayuk F, Chanswangphuwana C, Choe HK, et al. Journal article A Day 14 Endpoint for Acute GVHD Clinical Trials (2024) Spyrou N, Akahoshi Y, Kowalyk S, Morales G, Beheshti R, Aguayo-Hiraldo P, Al Malki MM, et al. Journal article Phase 2 study of natalizumab plus standard corticosteroid treatment for high-risk acute graft-versus-host disease (2023) Al Malki MM, London K, Baez J, Akahoshi Y, Hogan WJ, Etra A, Choe H, et al. Journal article The utility of biomarkers in acute GVHD prognostication (2023) Spyrou N, Akahoshi Y, Ayuk F, Holler E, Choe H, Etra A, Hogan WJ, et al. Journal article Caveolin Gene Expression Predicts Clinical Outcomes for Early-Stage HER2-Negative Breast Cancer Treated with Paclitaxel-Based Chemotherapy in the GeparSepto Trial (2023) Williams TM, Schneeweiss A, Jackisch C, Shen C, Weber KE, Fasching P, Denkert C, et al. Journal article Incidence, clinical presentation, risk factors, outcomes, and biomarkers in de novo late acute GVHD (2023) Akahoshi Y, Spyrou N, Hogan WJ, Ayuk F, DeFilipp Z, Weber D, Choe HK, et al. Journal article A genome-wide gene-environment interaction study of breast cancer risk for women of European ancestry (2023) Middha P, Wang X, Behrens S, Bolla MK, Wang Q, Dennis J, Michailidou K, et al. Journal article CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study (2023) Kang EY, Weir A, Meagher NS, Farrington K, Nelson GS, Ghatage P, Lee CH, et al. Journal article